Amarin free speech settlement delayed

The conclusion of a landmark off-label promotion lawsuit filed by Amarin Corp. plc (NASDAQ:AMRN) against FDA has been delayed as the parties continue to negotiate settlement terms. Amarin and FDA were scheduled to submit a settlement to the U.S. District Court for the Southern District of New York on Friday. Instead, Amarin's lawyers filed a letter stating that the parties "have engaged and continue to engage in settlement discussions in hopes of resolving this case," and requesting that the court give them until Dec. 17 to report back on the negotiations. ...